nach oben

Erschienen in:

2025 | OriginalPaper | Buchkapitel

5. Ersttrimesterscreening

verfasst von : Prof. Dr. med. MHBA Karl-Oliver Kagan, Prof. Dr. med. Harald Abele, Prof. Dr. med. Markus Hoopmann

Erschienen in: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Ersttrimester-Screening bei 11+ bis 13+ SSW gehört heute zu den essenziellen Untersuchungen in der Schwangerschaft. Lag anfänglich der Fokus der Untersuchung auf dem Screening auf Chromosomenstörungen, hat sich die Untersuchung heute zu einer Risikobeurteilung für genetische Auffälligkeiten im Allgemeinen und Trisomie 21 im Speziellen sowie zu einer Evaluation des Präeklampsierisikos und weiterer Schwangerschaftskomplikationen entwickelt, bis hin zu einer frühen Fehlbildungsdiagnostik. Dabei stellt die zellfreie DNA-Analyse im maternalen Blut nur eine Erweiterung des breiten Testansatzes im Rahmen des Ersttrimester- Screenings dar und sollte daher dieses nicht ersetzen.

Vorheriges Kapitel Ersttrimesterultraschall

Nächstes Kapitel Gehirn und Wirbelsäule

Agathokleous M, Chaveeva P, Poon LCY, Kosinski P, Nicolaides KH (2013) Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 41:247–261PubMedCrossRef

Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH (2005) Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26:154–157PubMedCrossRef

Bardi F, Kagan KO, Bilardo CM (2023) First-trimester screening strategies: a balance between costs, efficiency and diagnostic yield. Prenat Diagn 43:865–872PubMedCrossRef

Chang K-J, Seow K-M, Chen K-H (2023) Preeclampsia: recent advances in predicting, preventing, and managing the maternal and fetal life-threatening condition. Int J Environ Res Public Health 20:2994PubMedPubMedCentralCrossRef

Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94:387–402PubMedCrossRef

Galeva S, Gil MM, Konstantinidou L, Akolekar R, Nicolaides KH (2019) First-trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. Ultrasound Obstet Gynecol 53:804–809PubMedCrossRef

Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH (2016) Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19–24 weeks’ gestation. Am J Obstet Gynecol 214:619.e1–619.e17PubMedCrossRef

Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH (2017) Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 50:302–314PubMedCrossRef

Greco E, Gupta R, Syngelaki A, Poon LCY, Nicolaides KH (2012) First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 31:154–161PubMedCrossRef

Hui L, Bianchi DW (2020) Fetal fraction and noninvasive prenatal testing: what clinicians need to know. Prenat Diagn 40:155–163PubMedCrossRef

International Society of Ultrasound in Obstetrics and Gynecology, Bilardo CM, Chaoui R, Hyett JA, Kagan KO, Karim JN, Papageorghiou AT, Poon LC, Salomon LJ, Syngelaki A, Nicolaides KH (2023) ISUOG Practice Guidelines (updated): performance of 11–14-week ultrasound scan. Ultrasound Obstet Gynecol 61:127–143

Jani JC, Gil MM, Benachi A, Prefumo F, Kagan KO, Tabor A, Bilardo CM, Renzo GCD, Nicolaides KH (2020) Genome-wide cfDNA testing of maternal blood. Ultrasound Obstet Gynecol 55:13–14PubMedCrossRef

Judah H, Gil MM, Syngelaki A, Galeva S, Jani J, Akolekar R, Nicolaides KH (2021) Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10–14 weeks and meta-analysis. Ultrasound Obstet Gynecol 58:178–189PubMedCrossRef

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008a) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31:493–502PubMedCrossRef

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH (2008b) Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-A. Hum Reproduction 23:1968–1975CrossRef

Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH (2009) Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol 33:657–664PubMedCrossRef

Kagan KO, Sroka F, Sonek J, Abele H, Lüthgens K, Schmid M, Wagner P, Brucker S, Wallwiener D, Hoopmann M (2018) First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol 51:437–444PubMedCrossRef

Kagan KO, Sonek J, Kozlowski P (2022) Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet 305:825–835PubMedPubMedCentralCrossRef

Karim JN, Roberts NW, Salomon LJ, Papageorghiou AT (2017) Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance. Ultrasound Obstet Gynecol 50:429–441PubMedCrossRef

Karim JN, Bradburn E, Roberts N, Papageorghiou AT; ACCEPTS study (2022) First trimester ultrasound for the detection of fetal heart anomalies: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 59:11–25

Kristensen SE, Ekelund CK, Sandager P, Jørgensen FS, Hoseth E, Sperling L, Balaganeshan SB, Hjortshøj TD, Gadsbøll K, Wright A, Wright D, McLennan A, Sundberg K, Petersen OB (2023) Risks and pregnancy outcome after fetal reduction in dichorionic twin pregnancies: a Danish national retrospective cohort study. Am J Obstet Gynecol 228:590.e1–590.e12PubMedCrossRef

Lüthgens K, Grati FR, Sinzel M, Häbig K, Kagan KO (2020) Confirmation rate of cell free DNA screening for sex chromosomal abnormalities according to the method of confirmatory testing. Prenat Diagn 41:1258–1263PubMedCrossRef

Lüthgens K, Häbig K, Sonek J, Kagan KO (2023) Screen-positive rate in cell free DNA screening for trisomy 21. Prenat Diagn 43:1536–1543PubMedCrossRef

Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K (2011) A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 37:38–47PubMedCrossRef

Mellis R, Oprych K, Scotchman E, Hill M, Chitty LS (2022) Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis. Prenat Diagn 42:662–685PubMedPubMedCentralCrossRef

Minnella GP, Crupano FM, Syngelaki A, Zidere V, Akolekar R, Nicolaides KH (2020) Diagnosis of major heart defects by routine first-trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. Ultrasound Obstet Gynecol 55:637–644PubMedCrossRef

Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ (2016) Pre-eclampsia. Lancet 387:999–1011PubMedCrossRef

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, Cuckle H, Musci TJ, Wapner RJ (2015) Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 372:1589–1597PubMedCrossRef

O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH (2016) Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol 214:103.e1–103.e12PubMedCrossRef

Peyvandi S, Santiago VD, Chakkarapani E, Chau V, Campbell A, Poskitt KJ, Xu D, Barkovich AJ, Miller S, McQuillen P (2016) Association of prenatal diagnosis of critical congenital heart disease with postnatal brain development and the risk of brain injury. JAMA Pediatr 170:e154450PubMedPubMedCentralCrossRef

Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH (2011) Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy. Fetal Diagn Ther 30:108–115PubMedCrossRef

Poon LC, Nicolaides KH (2014) First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 34:618–627PubMedCrossRef

Prodan NC, Wiechers C, Geipel A, Walter A, Siegmann HJ, Kozlowski P, Hoopmann M, Kagan KO (2022) Universal cell free DNA or contingent screening for Trisomy 21: does it make a difference? A comparative study with real data. Fetal Diagn Ther 49:85–94PubMedCrossRef

Rolnik DL, Wright R, Poon LC, O’Gorman N, Syngelaki A, Matallana CP, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH (2017a) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 377:613–622PubMedCrossRef

Rolnik DL, Wright D, Poon LC, Syngelaki A, O’Gorman N, Matallana CP, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Gavish KT, Nicolaides KH (2017b) ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 50:492–495PubMedCrossRef

Rose NC, Barrie ES, Malinowski J, Jenkins GP, McClain MR, LaGrave D, Leung ML, ACMG Professional Practice and Guidelines Committee (2022) Systematic evidence-based review: the application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies. Genet Med 24:1379–1391PubMedCrossRef

Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R (2019) Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. Ultrasound Obstet Gynecol 54:442–451PubMedCrossRef

Santorum M, Wright D, Syngelaki A, Karagioti N, Nicolaides KH (2017) Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound Obstet Gynecol 49:714–720PubMedCrossRef

Savoia F, Scala C, Coppola M, Riemma G, Vitale SG, Mikuš M, Schiattarella A, Verde ML, Colacurci N, Franciscis PD, Morlando M (2022) The diagnostic performance of the ductus venosus for the detection of cardiac defects in the first trimester: a systematic review and diagnostic test accuracy meta-analysis. Arch Gynecol Obstet 308:435–451PubMedPubMedCentralCrossRef

Scala C, Morlando M, Familiari A, Maggiore ULR, Ferrero S, D’Antonio F, Khalil A (2017) Fetal tricuspid regurgitation in the first trimester as a screening marker for congenital heart defects: Systematic review and metanalysis. Fetal Diagn Ther 42:1–8PubMedCrossRef

Snijders RJM, Sebire NJ, Nicolaides KH (1995) Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 10:356–367PubMedCrossRef

Sorrenti S, Mascio DD, Khalil A, Persico N, D’Antonio F, Zullo F, D’Ambrosio V, Greenberg G, Hasson J, Vena F, Muzii L, Brunelli R, Giancotti A (2023) Pregnancy and perinatal outcomes of early vs late selective termination in dichorionic twin pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol 61:552–558PubMedCrossRef

Spingler T, Sonek J, Hoopmann M, Prodan N, Abele H, Kagan KO (2023) Complication rate after termination of pregnancy for fetal defects. Ultrasound Obstet Gynecol 62:88–93PubMedCrossRef

Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH (2015) First-trimester screening for gestational diabetes mellitus based on maternal characteristics and history. Fetal Diagn Ther 38:14–21PubMedCrossRef

van Velzen CL, Haak MC, Reijnders G, Rijlaarsdam MEB, Bax CJ, Pajkrt E, Hruda J, Galindo-Garre F, Bilardo CM, de Groot CJM, Blom NA, Clur SA (2014) Prenatal detection of transposition of the great arteries reduces mortality and morbidity. Ultrasound Obstet Gynecol 45:320–325CrossRef

van Velzen CL, Ket JCF, van de Ven PM, Blom NA, Haak MC (2017) Systematic review and meta-analysis of the performance of second-trimester screening for prenatal detection of congenital heart defects. Int J Gynaecol Obstet 140:137–145PubMedCrossRef

Wagner P, Sonek J, Hoopmann M, Abele H, Kagan KO (2016) First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan. Ultrasound Obstet Gynecol 48:446–451PubMedCrossRef

Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH (2008) A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31:376–383PubMedCrossRef

Wright D, Spencer K, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH (2010) First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 36:404–411PubMedCrossRef

Wright D, Abele H, Baker A, Kagan KO (2011) Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 38:309–313PubMedCrossRef

Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH (2012) A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 32:171–178PubMedCrossRef

Wulff CB, Rode L, Rosthøj S, Hoseth E, Petersen OB, Tabor A (2018) Transvaginal sonographic cervical length in first and second trimesters in a low-risk population: a prospective study. Ultrasound Obstet Gynecol 51:604–613PubMedCrossRef

Yaron Y (2016) The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat Diagn 36:391–396PubMedCrossRef

Zumaeta AM, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH (2020) Screening for trisomy at 11–13 weeks’ gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol 56:408–415CrossRef

Kagan KO, Sonek J, Wagner P, Hoopmann M (2017a) Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities. Arch Gynecol Obstet 296:645–651PubMedCrossRef

Kagan KO, Sonek J, Wagner P, Hoopmann M (2017b) Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for other major defects and pregnancy complications. Arch Gynecol Obstet 296:635–643PubMedCrossRef

Titel: Ersttrimesterscreening
verfasst von: Prof. Dr. med. MHBA Karl-Oliver Kagan
Prof. Dr. med. Harald Abele
Prof. Dr. med. Markus Hoopmann
Verlag: Springer Berlin Heidelberg
Buch: Ultraschalldiagnostik in Geburtshilfe und Gynäkologie
Print ISBN: 978-3-662-67372-0

Electronic ISBN: 978-3-662-67373-7

Copyright-Jahr: 2025
DOI: https://doi.org/10.1007/978-3-662-67373-7_5

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten